The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions Early evidence suggests BPC 157 repairs tissue rather than just dulling symptoms. To read more, tap the link in bio. The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Orthopedic Use of BPC 157 Sports Med Review